Literature DB >> 25214510

Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

Mireia Sospedra1, Sven Schippling1, Sara Yousef2, Ilijas Jelcic3, Silvia Bofill-Mas4, Raquel Planas1, Jan-Patrick Stellmann2, Viktoria Demina5, Paola Cinque6, Robert Garcea7, Therese Croughs8, Rosina Girones4, Roland Martin1.   

Abstract

Progressive multifocal leukoencephalopathy is a currently untreatable infection of the brain. Here, we demonstrate in 2 patients that treatment with interleukin 7, JC polyomavirus (JCV) capsid protein VP1, and a Toll-like receptor 7 agonist used as adjuvant, was well tolerated, and showed a very favorable safety profile and unexpected efficacy that warrant further investigation.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  IL-7; JC virus; VP1; progressive multifocal leukoencephalopathy

Mesh：

Substances：

Year:  2014        PMID： 25214510      PMCID： PMC4650775          DOI： 10.1093/cid/ciu682

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.

Authors:  C Goldmann; H Petry; S Frye; O Ast; S Ebitsch; K D Jentsch; F J Kaup; F Weber; C Trebst; T Nisslein; G Hunsmann; T Weber; W Lüke
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.

Authors:  P Cinque; C Pierotti; M G Viganò; A Bestetti; C Fausti; D Bertelli; A Lazzarin
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 3.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

4.  Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy.

Authors:  T Weber; C Trebst; S Frye; P Cinque; L Vago; C J Sindic; W J Schulz-Schaeffer; H A Kretzschmar; W Enzensberger; G Hunsmann; W Lüke
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

5.  Anti-JC virus antibodies: implications for PML risk stratification.

Authors:  Leonid Gorelik; Michaela Lerner; Sarah Bixler; Mary Crossman; Brian Schlain; Kenneth Simon; Amy Pace; Anne Cheung; Ling Ling Chen; Melissa Berman; Fairuz Zein; Ewa Wilson; Ted Yednock; Alfred Sandrock; Susan E Goelz; Meena Subramanyam
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

6.  IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology.

Authors:  Marc Pellegrini; Thomas Calzascia; Jesse G Toe; Simon P Preston; Amy E Lin; Alisha R Elford; Arda Shahinian; Philipp A Lang; Karl S Lang; Michel Morre; Brigitte Assouline; Katharina Lahl; Tim Sparwasser; Thomas F Tedder; Ji-Hye Paik; Ronald A DePinho; Sameh Basta; Pamela S Ohashi; Tak W Mak
Journal:  Cell       Date:  2011-02-03       Impact factor: 41.582

7.  Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

Authors:  Lilian Aly; Sara Yousef; Sven Schippling; Ilijas Jelcic; Petra Breiden; Jakob Matschke; Robert Schulz; Silvia Bofill-Mas; Louise Jones; Viktorya Demina; Michael Linnebank; Graham Ogg; Rosina Girones; Thomas Weber; Mireia Sospedra; Roland Martin
Journal:  Brain       Date:  2011-09       Impact factor: 13.501

Review 8.  Harnessing the biology of IL-7 for therapeutic application.

Authors:  Crystal L Mackall; Terry J Fry; Ronald E Gress
Journal:  Nat Rev Immunol       Date:  2011-05       Impact factor: 53.106

9.  Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.

Authors:  Sarah Gheuens; Evelyn Bord; Santosh Kesari; David M Simpson; Rajesh T Gandhi; David B Clifford; Joseph R Berger; Long Ngo; Igor J Koralnik
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

10.  Real-time, quantitative PCR assays for the detection of virus-specific DNA in samples with mixed populations of polyomaviruses.

Authors:  Achintya Pal; Lev Sirota; Thomas Maudru; Keith Peden; Andrew M Lewis
Journal:  J Virol Methods       Date:  2006-03-09       Impact factor: 2.014
View more
  27 in total

1.  Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

2.  Brief Report: Role of Thymic Reconstitution in the Outcome of AIDS-Related PML.

Authors:  Spyridon G Chalkias; Sarah Gheuens; Evelyn Bord; Stephanie Batson; Igor J Koralnik
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

Review 3.  [Progressive multifocal leukoencephalopathy].

Authors:  C Warnke; M P Wattjes; O Adams; H-P Hartung; R Martin; T Weber; M Stangel
Journal:  Nervenarzt       Date:  2016-12       Impact factor: 1.214

Review 4.  Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls.

Authors:  Dietrich Haubenberger; David B Clifford
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

5.  Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient.

Authors:  Aabha Oza; Michael P Rettig; Phil Powell; Kathryn O'Brien; David B Clifford; Julie Ritchey; Leah Gehrs; Julia Hollaway; Eugene Major; Todd A Fehniger; Christopher A Miller; Patrick Soon-Shiong; Amy Rock; John F DiPersio
Journal:  Blood Adv       Date:  2020-06-09

6.  Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia.

Authors:  Asaff Harel; Sam Horng; Tarah Gustafson; Anil Ramineni; Rebecca Straus Farber; Michelle Fabian
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

7.  JC polyomavirus mutants escape antibody-mediated neutralization.

Authors:  Upasana Ray; Paola Cinque; Simonetta Gerevini; Valeria Longo; Adriano Lazzarin; Sven Schippling; Roland Martin; Christopher B Buck; Diana V Pastrana
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

Review 8.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

9.  Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.

Authors:  Dennis W Raisch; John A Rafi; Cheng Chen; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2016-06-20       Impact factor: 4.250

Review 10.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.